Tirzepatide (Mounjaro, Zepbound): The Complete Guide

Tirzepatide is a once-weekly injectable medicine that switches on two hormone receptors at once: the GIP receptor and the GLP-1 receptor^[1,2]. It lowers calorie intake, slows stomach emptying and helps control blood sugar^[1,2]. Eli Lilly sells it under two names in the US: Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea^[1,2]. In the European Union there’s no Zepbound: Mounjaro covers both diabetes and weight management^[3]. In the SURMOUNT-1 trial, in adults without diabetes, weight fell by an average of 15.0% to 20.9% over 72 weeks depending on the dose, vs. 3.1% on placebo^[8]. The most common side effects are digestive^[1,2].

This guide brings together the FDA labels for Mounjaro and Zepbound, the EU label from the European Medicines Agency (EMA) and the main trials, with every source linked. How the whole drug family works is in what GLP-1 medications are. None of this replaces a visit: starting, adjusting or stopping tirzepatide is a decision for your prescriber, made with you.

What tirzepatide is and how it differs from semaglutide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It mimics two hormones your gut releases when you eat: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both help regulate insulin and appetite.

According to section 12 of the US labels, tirzepatide binds to and activates both the GIP and GLP-1 receptors, and a fatty-acid chain lets it bind to albumin, a blood protein, which prolongs its half-life^[1,2]. Both receptors are found in areas of the brain involved in appetite regulation^[1]. The Zepbound label describes these effects^[1]:

• Appetite. Tirzepatide decreases calorie intake, an effect likely mediated by appetite.
• Stomach emptying. It delays gastric emptying; the delay is largest after the first dose and diminishes over time.
• Blood sugar. It stimulates insulin release in a glucose-dependent way, reduces glucagon and increases insulin sensitivity.
• Body composition. It lowers body weight with greater fat mass loss than lean mass loss.

The EU label goes into more detail. It says tirzepatide’s activity on the GIP receptor is similar to the natural hormone’s, and its activity on the GLP-1 receptor is lower than natural GLP-1’s^[3]. It also reports that tirzepatide increases feelings of satiety and fullness, decreases hunger, and reduces the intensity of food cravings and the preference for high-sugar and high-fat foods^[3].

The difference from semaglutide (Ozempic, Wegovy) is the mechanism. Semaglutide acts only on the GLP-1 receptor^[19], while tirzepatide adds the GIP receptor^[1,2]. The head-to-head trials further down show what that means in practice.

What Mounjaro and Zepbound are approved for

The active ingredient is the same everywhere; the brand names and approved uses change. The table only includes what I’ve checked in an official label.

BMI is body mass index, in kg/m². A weight-related condition (comorbidity) is a health problem linked to weight: the EU label gives high blood pressure, abnormal blood fats, obstructive sleep apnea, cardiovascular disease, prediabetes or type 2 diabetes as examples^[3]. The BMI calculator works out yours and explains what BMI doesn’t measure.

A few details the table can’t hold:

• Mounjaro and Zepbound contain the same thing. Same active ingredient, strengths and presentations^[1,2]. The FDA approved Zepbound on November 8, 2023^[5], noting that its active ingredient was already approved as Mounjaro^[6], and added sleep apnea on December 20, 2024^[5,7]. The Zepbound label says coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended^[1]. Approved uses, list prices and insurance for each brand are compared in Mounjaro vs. Zepbound. The sleep apnea trial and approval are covered in Zepbound for sleep apnea.
• There’s no Zepbound in Europe. Mounjaro was first authorized in the EU on September 15, 2022, and today one label covers both diabetes and weight management^[3]. Results in obstructive sleep apnea and in heart failure with preserved ejection fraction appear as trial results in section 5.1, not as separate indications^[3] (see the SUMMIT trial summary). So the US sleep apnea approval has no EU equivalent.
• Mounjaro’s heart indication is new. The FDA added it in August 2026^[2,4], based on the SURPASS-CVOT trial described below.
• Latin America. Registration in Mexico and Chile, where I’ve checked it, is covered in the Spanish edition of this guide (in Spanish).

Pens, vials and strengths

Tirzepatide comes in six strengths, from 2.5 to 15 mg per dose, in 2.5 mg steps. In the US, both brands share the same four presentations^[1,2]:

Sources: section 3 of the US labels for Zepbound^[1] and Mounjaro^[2]; sections 1 and 2 of the EU label^[3].

Three practical details from the US labels^[1,2]:

• Each dose from a KwikPen or multi-dose vial contains 5.4 mg of benzyl alcohol, a preservative.
• Patients and caregivers should be trained on the injection technique for the specific presentation prescribed, and trained again if it changes.
• A KwikPen must never be shared between people, even if the needle is changed.

How to get rid of used pens and needles, and how to travel with them, is in disposing of pens and needles, and travelling.

What the clinical trials show

The main data come from two programs funded by Eli Lilly: SURMOUNT (weight management) and SURPASS (type 2 diabetes)^{[8,9,10,11,12,13]}. All the trials below are randomized. In the weight trials, everyone also got lifestyle counseling: instruction on a reduced-calorie diet of about 500 kcal a day below needs, and advice to do at least 150 minutes of physical activity a week^[1].

SURMOUNT-1: adults with obesity or overweight, without diabetes

SURMOUNT-1 enrolled 2,539 adults without diabetes, with a BMI of 30 or more, or 27 or more with at least one weight-related complication^[8]. They weighed an average of 104.8 kg (231 lb) at the start^[8]. They were randomly assigned to one of three tirzepatide doses or placebo for 72 weeks, with a dose-escalation period of up to 20 weeks^[1]. There’s a plain-language summary in our SURMOUNT-1 trial page.

Sources: Table 2 of the Zepbound label, section 14.1^[1]; discontinuations from the published paper^[8].

These figures count everyone who was randomized, whether or not they kept taking the drug, and the US label and the paper report the same averages^[1,8]. The EU label publishes somewhat larger figures, −16.0%, −21.4% and −22.5%, vs. −2.4% on placebo^[3], because it uses a different analysis, focused on the effect while people stay on treatment. Neither predicts any one person’s result, because the response varies a lot; more in how much weight people lose on GLP-1 medications.

The EU label adds a 176-week follow-up of the participants who had prediabetes: 1.2% of those on tirzepatide progressed to type 2 diabetes, vs. 12.6% on placebo^[3].

SURMOUNT-2: adults with type 2 diabetes

SURMOUNT-2 enrolled 938 adults with type 2 diabetes, a BMI of 27 or more and an HbA1c of 7% to 10%^[9]. HbA1c reflects average blood sugar over the past two to three months. According to the Zepbound label, 60% identified as Hispanic or Latino^[1]. It compared 10 and 15 mg with placebo for 72 weeks (trial summary).

Source: Tables 2 and 3 of the Zepbound label^[1]. CI is the confidence interval, the range where the true effect probably lies.

As with other drugs in this family, people with type 2 diabetes lost less weight than people without it^[1,8,9].

SURPASS-2: vs. semaglutide 1 mg in type 2 diabetes

SURPASS-2 enrolled 1,879 adults with type 2 diabetes who were taking metformin, with an average HbA1c of 8.28% and an average weight of 93.7 kg (207 lb)^[10]. It compared tirzepatide 5, 10 and 15 mg with semaglutide 1 mg for 40 weeks (trial summary).

Source: the published paper^[10].

Nausea affected 17% to 22% of people on tirzepatide and 18% on semaglutide^[10]. The main limits: it used semaglutide 1 mg, not the 2 mg dose the Ozempic label now includes^[19], and it was open-label, so participants knew which drug they were taking^[10].

SURMOUNT-5: vs. semaglutide 2.4 mg in obesity

SURMOUNT-5 enrolled 751 adults with obesity, or with overweight and at least one weight-related condition, without diabetes^[11]. Each group got the highest dose they tolerated for 72 weeks: tirzepatide 10 or 15 mg, or semaglutide 1.7 or 2.4 mg, the Wegovy dose^[11]. There’s a trial summary too.

• Weight: −20.2% on tirzepatide (95% CI −21.4 to −19.1) and −13.7% on semaglutide (95% CI −14.9 to −12.6), an estimated difference of −6.5 points (95% CI −8.1 to −4.9)^[11].
• Waist: −18.4 cm (7.2 in) vs. −13.0 cm (5.1 in)^[11].
• Side effects: mostly digestive in both groups, and mostly mild to moderate^[11].

The US labels don’t include this trial. The EU label does, with its own analysis: −21.6% vs. −15.4%, a difference of −6.2 points (95% CI −7.8 to −4.6)^[3]. The trial was funded by tirzepatide’s manufacturer, was open-label and had no placebo group^[11].

Sleep apnea: SURMOUNT-OSA

This is the trial behind Zepbound’s US sleep apnea approval^[1,7]. It was really two 52-week trials in a total of 469 adults with moderate to severe obstructive sleep apnea and obesity, without type 2 diabetes: one in people not using positive airway pressure (PAP, such as CPAP) and one in people using it^[1]. The main measure was the apnea-hypopnea index (AHI), the number of breathing pauses or shallow-breathing episodes per hour of sleep.

Source: Table 9 of the Zepbound label, section 14.2^[1]. More detail in the SURMOUNT-OSA trial summary.

Heart outcomes: SURPASS-CVOT

SURPASS-CVOT enrolled 13,299 adults with type 2 diabetes and established cardiovascular disease and compared tirzepatide with dulaglutide 1.5 mg, another weekly diabetes injection, over a median of about 4 years^[2,12]. For a heart attack, stroke or cardiovascular death, the hazard ratio was 0.92 (95.3% CI 0.83 to 1.01): tirzepatide was noninferior to dulaglutide, but superiority was not established^[2]. The hazard ratio compares risk between groups over time, and noninferior means “not worse”. This trial is the basis of Mounjaro’s new US cardiovascular indication^[2]. There’s a trial summary.

How the dose is increased, according to the labels

Tirzepatide isn’t started at the final dose: it’s raised in 2.5 mg steps to reduce digestive side effects^[1,2]. The schedule below is the Zepbound label’s. This isn’t dosing advice: your prescriber decides your schedule, based on how you tolerate it, what it’s prescribed for and your other medicines.

Source: Zepbound label, sections 2.1 and 2.2^[1]. The recommended maintenance doses are 5, 10 or 15 mg for weight reduction and long-term maintenance, and 10 or 15 mg for sleep apnea^[1]. The label also says to consider response and tolerability when choosing the maintenance dose, and a lower maintenance dose if one isn’t tolerated^[1].

The other labels word it differently:

• Mounjaro (US). It starts at 2.5 mg once weekly; if more blood sugar control is needed, the dose goes up in 2.5 mg steps after at least 4 weeks on the current dose, to a maximum of 15 mg in adults and 10 mg in children 10 and older^[2]. Unlike Zepbound’s, the Mounjaro label doesn’t list fixed maintenance doses^[2].
• Mounjaro (EU). 2.5 mg for 4 weeks, then 5 mg; maintenance doses of 5, 10 or 15 mg in adults, and 5 or 10 mg in children 10 and older with type 2 diabetes^[3].

All three labels agree on how it’s given: once weekly, at any time of day, with or without meals, under the skin of the abdomen or thigh, or the back of the upper arm if someone else injects it, rotating the site each time^[1,2,3]. When it’s added to insulin or a sulfonylurea (another type of diabetes medicine), the labels say lowering the dose of those medicines may be considered to reduce the risk of low blood sugar^[1,2,3]. Injection-site problems and how they’re handled are in injection site reactions.

Tirzepatide side effects and how common they are

The most common side effects are digestive. Both US labels say most nausea, vomiting and diarrhea happened during dose increases and decreased over time^[1,2]. This table is from Zepbound’s two placebo-controlled weight trials, SURMOUNT-1 and SURMOUNT-2, with 2,519 adults treated for up to 72 weeks^[1].

Source: Table 1 of the Zepbound label, section 6.1^[1]. It lists side effects seen in at least 2% of people on tirzepatide and more often than on placebo. I show 12 of its 16 rows; the other four are allergic reactions, gas, bloating and low blood pressure, each in 5% or fewer of people on tirzepatide^[1].

How often they happen, in numbers

Sections 5 and 6 of the Zepbound label add more figures from the same two trials, plus reports received after approval^[1]:

• Any digestive side effect: 56% on each dose vs. 30% on placebo. 1.9%, 3.3% and 4.3% stopped treatment because of them on 5, 10 and 15 mg, vs. 0.5% on placebo.
• Severe digestive side effects: 1.7%, 2.5% and 3.1% vs. 1% on placebo.
• Stopped for any side effect: 4.8%, 6.3% and 6.7% vs. 3.4%, mostly in the first few months and because of digestive symptoms.
• Gallbladder: gallstones in 1.1% vs. 1%, gallbladder inflammation (cholecystitis) in 0.7% vs. 0.2%, and gallbladder removal in 0.2% vs. none; these events were associated with weight reduction.
• Heart rate: an average increase of 1 to 3 beats per minute.
• Low blood sugar in type 2 diabetes (SURMOUNT-2): 4.2% vs. 1.3% on placebo; 10.3% in people also taking a sulfonylurea, vs. 2.1% in those who weren’t.
• Hair loss: 7.1% of women vs. 0.5% of men on tirzepatide; it was associated with weight reduction. More in hair loss on GLP-1 medications.
• Reported after approval: acute pancreatitis, sometimes fatal; ileus and intestinal obstruction; severe constipation, including fecal impaction; anaphylaxis and angioedema; and acute kidney failure, sometimes requiring dialysis. Because these come from voluntary reports, their frequency can’t be estimated^[1].

In Mounjaro’s type 2 diabetes trials, digestive side effects were less frequent: nausea in 12%, 15% and 18% vs. 4% on placebo, and decreased appetite in 5%, 10% and 11% vs. 1%^[2]. Those were different people over a shorter time, so the two tables can’t be ranked; I compare them side by side in Mounjaro vs. Zepbound. In children 10 and older, the Mounjaro label reports more vomiting, abdominal pain and low blood sugar than in adults^[2].

For the two most common problems, I have guides on what to eat with nausea and constipation on GLP-1 medications, plus diarrhea and acid reflux. The symptom diary helps you track them to show your doctor. One symptom needs urgent attention: the Medication Guides tell patients to stop and call their healthcare provider right away for severe pain in the stomach area that won’t go away, with or without nausea or vomiting, sometimes felt from the abdomen to the back, because it can be pancreatitis^[1,2].

Safety signals regulators have reviewed

I only include what regulators have concluded, with the date.

Dysesthesia and delayed stomach emptying

In scientific conclusions dated December 12, 2024, the EMA’s safety committee (PRAC) found a causal link between tirzepatide and dysesthesia (abnormal skin sensations, such as tingling or burning) “at least a reasonable possibility”, and the same for delayed gastric emptying^[14]. It asked for both to be added to the EU label. The committee for human medicines (CHMP) agreed and concluded that the benefit-risk balance was unchanged^[14]. In the US, the Zepbound label reports dysesthesia in 0.2% to 0.4% of people on tirzepatide vs. 0.1% on placebo^[1].

Suicidal thoughts

On January 13, 2026, the FDA announced that it had found no increased risk of suicidal thoughts or behavior with these drugs, after analyzing 91 trials with 107,910 patients and real-world data from more than 2.2 million people^[16]. It asked for the warning to be removed from the labels of Saxenda, Wegovy and Zepbound^[16]. The current Zepbound label lists the suicidal behavior and ideation warning as removed in February 2026^[1]. In Europe, the April 2024 review found no causal link for five GLP-1 receptor agonists, but it didn’t include tirzepatide^[15]. If you notice mood changes during any treatment, talk to your doctor.

Thyroid tumors: the boxed warning

Both US labels open with a boxed warning, the FDA’s most prominent kind: in rats, tirzepatide caused thyroid C-cell tumors, and it’s unknown whether it causes them, including medullary thyroid carcinoma (MTC), in humans^[1,2]. That’s why, in the US, it’s contraindicated in people with a personal or family history of MTC or with multiple endocrine neoplasia syndrome type 2 (MEN 2)^[1,2]. The labels ask prescribers to explain the symptoms of thyroid tumors: a lump in the neck, trouble swallowing, shortness of breath or persistent hoarseness, and note that routine calcitonin tests or thyroid ultrasound are of uncertain value for early detection^[1,2].

Europe sees the same data differently. The EU label describes the same thyroid C-cell tumors in rats in its preclinical section (5.3), also of unknown relevance to humans, but it doesn’t make that history a contraindication^[3].

Illegal, counterfeit and compounded products

This risk isn’t in the labels, but regulators keep warning about it:

• United States. The FDA says compounded drugs aren’t FDA-approved, so the agency doesn’t review them for safety, effectiveness or quality before they’re sold^[17]. As of May 31, 2026, it had received more than 730 adverse event reports involving compounded tirzepatide^[17]. Some may be linked to doses beyond what the approved labels allow: more product per dose, more frequent doses or faster increases^[17].
• European Union. On September 3, 2025, the EMA and the heads of the national agencies warned of a sharp rise in illegal medicines sold as semaglutide, liraglutide and tirzepatide, often through fraudulent websites and social media^[18]. They may not contain the stated active ingredient at all^[18].

That’s why you won’t find purchase links or sourcing tips on this site. If you’re using or considering a compounded product, tell your doctor.

Contraindications and warnings in the labels

In the US, tirzepatide is contraindicated in people with a personal or family history of MTC or with MEN 2, and in people with a known serious hypersensitivity to tirzepatide or any of its ingredients^[1,2]. In the EU, the only contraindication is hypersensitivity to tirzepatide or its ingredients^[3]. The main warnings and precautions in sections 5 to 8 of the US labels are^[1,2]:

• Acute pancreatitis. Fatal and nonfatal hemorrhagic or necrotizing pancreatitis has been observed with GLP-1 receptor agonists or tirzepatide; treatment should be stopped if pancreatitis is suspected. The EU label adds that it hasn’t been studied in people with a history of pancreatitis, should be used with caution in them, and shouldn’t be restarted if pancreatitis is confirmed^[3].
• Low blood sugar. The risk goes up with insulin or an insulin secretagogue such as a sulfonylurea.
• Dehydration and the kidneys. There have been reports of acute kidney injury, sometimes requiring dialysis, mostly in people whose nausea, vomiting or diarrhea led to dehydration. The hydration guide covers how much to drink.
• Severe digestive disease. Not recommended in people with severe gastroparesis, a condition where the stomach empties very slowly.
• Gallbladder disease. If gallbladder inflammation is suspected, gallbladder tests and follow-up are needed.
• Diabetic retinopathy. Temporary worsening has been reported with rapid improvement in blood sugar; people with a history of diabetic retinopathy should be monitored.
• Anesthesia or deep sedation. There have been rare reports of food being inhaled into the lungs (pulmonary aspiration) during general anesthesia or deep sedation in people on GLP-1 receptor agonists, despite following fasting instructions; patients should tell their healthcare providers about any planned surgery or procedure.
• Allergic reactions. Serious reactions such as anaphylaxis and angioedema have been reported; if one happens, treatment should be stopped and medical help sought promptly.
• Pregnancy. Here the labels differ. Zepbound’s says weight loss offers no benefit during pregnancy and may cause fetal harm, and to stop Zepbound when a pregnancy is recognized^[1]. Mounjaro’s says it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus^[2]. The EU label recommends contraception for women who could become pregnant and stopping tirzepatide at least 1 month before a planned pregnancy^[3].
• Birth-control pills. The two regions disagree, and I cover both in the FAQ and in period changes on Ozempic or Mounjaro.
• Breastfeeding. After a single 5 mg dose, tirzepatide was undetectable or present at low levels in breast milk^[1,2,3]. The US labels ask for the benefits of breastfeeding to be weighed against the mother’s need for the drug^[1,2]; the EU label says tirzepatide could be considered for use during breastfeeding^[3]. It’s a decision to make with your doctor.
• Other oral medicines. Because it delays stomach emptying, tirzepatide may affect how other oral medicines are absorbed; people on drugs with a narrow therapeutic index, such as warfarin, should be monitored.
• Children. Zepbound’s safety and effectiveness haven’t been established in children^[1]. Mounjaro is approved for type 2 diabetes from age 10^[2].

What to eat and how to protect your muscle

The labels present tirzepatide as an addition to a reduced-calorie diet and increased physical activity, not a replacement for them^[1]. The SURMOUNT results were obtained with that counseling^[1].

With less appetite, the challenge isn’t eating less, it’s eating well while hungry less often: enough protein, fiber, fluids and nutrients in smaller portions. The goal isn’t to eat as little as possible. If you’re skipping meals out of fear of symptoms, or your relationship with food is getting worse, ask a health professional for help.

On muscle, the EU label cites a SURMOUNT-1 sub-study that used DEXA scans (a body composition X-ray): fat mass fell more than lean mass, and visceral fat fell too^[3]. Even so, part of the weight lost is lean mass. I go through the numbers in protein and muscle on GLP-1 medications and in the body composition sub-study summary. To put it into practice, there’s what to eat on GLP-1 medications and the daily protein calculator, which gives you a target to discuss with your doctor or a registered dietitian.

What happens when you stop tirzepatide

When treatment stops, much of the lost weight tends to come back. Stopping, lowering or changing it is your prescriber’s call.

In SURMOUNT-4, 783 adults without diabetes took tirzepatide for 36 weeks, at the highest tolerated dose of 10 or 15 mg^[13]. The 670 who completed that phase had lost an average of 20.9%^[1,13]. They were then randomly assigned to keep taking tirzepatide or switch to placebo for 52 weeks.

Sources: Table 6 of the Zepbound label^[1] and the published paper^[13].

The difference was −19.4 points (95% CI −21.2 to −17.7)^[1]. The placebo group’s average weight at week 88 was still below where it started^[13]. The limits: the first phase selected people who tolerated the drug, and no eating strategy after stopping was tested^[13]. I compare tirzepatide and semaglutide on this in what happens when you stop a GLP-1 medication.

Availability and cost

Both brands need a prescription. What you pay depends on your insurance, the use it’s prescribed for and the manufacturer’s programs, so I don’t give figures here or link to pharmacies.

• List prices and Medicare. Mounjaro vs. Zepbound covers Lilly’s published list prices for each brand and how Medicare treats each use, with sources and dates.
• Your own math. The monthly cost calculator works out the cost per dose, every 4 weeks and per year for the US, Spain and Mexico, with each price’s source.
• Outside the US. In the EU, Mounjaro is the only tirzepatide brand, with one label for diabetes and weight^[3]. Prices and coverage in Spain and Mexico are in the Spanish edition of this guide (in Spanish).

Mounjaro vs. Ozempic

Ozempic contains semaglutide, which activates only the GLP-1 receptor; Mounjaro contains tirzepatide, which also activates the GIP receptor^[2,19]. In the US both are type 2 diabetes medicines: the Ozempic label covers blood sugar control in adults with type 2 diabetes, plus heart and kidney risk reduction in some of them^[19]. The head-to-head data are in SURPASS-2 and SURMOUNT-5, above. Choosing one or the other is a clinical decision that depends on the approved use, medical history and tolerance. The full comparison is in Ozempic vs. Mounjaro, and the brand names behind each molecule are in GLP-1 generic and brand names. For weight management, Zepbound and Wegovy are compared in Zepbound vs. Wegovy.

Frequently asked questions

Is 5 mg a maintenance dose?

For Zepbound, yes: the maintenance doses are 5, 10 or 15 mg for weight, and 10 or 15 mg for sleep apnea, and 2.5 mg is only a starting dose^[1]. The US Mounjaro label names no maintenance doses, and the EU label lists 5, 10 or 15 mg in adults^[2,3]. Which dose fits a given person is for the prescriber to decide.

Are Mounjaro and Zepbound the same medicine?

Same active ingredient, strengths and maker, approved in the US for different uses: Mounjaro for type 2 diabetes, including heart-risk reduction, Zepbound for weight management and sleep apnea^[1,2]. In Europe, Mounjaro covers diabetes and weight, and Zepbound isn’t sold^[3]. More in Mounjaro vs. Zepbound.

Tirzepatide vs semaglutide: which works better?

For weight, the head-to-head trial in obesity without diabetes is SURMOUNT-5: at 72 weeks, on the highest dose each person tolerated, weight fell 20.2% on tirzepatide and 13.7% on semaglutide, an estimated difference of 6.5 percentage points^[11]. In type 2 diabetes, SURPASS-2 found larger drops in HbA1c and weight with tirzepatide than with semaglutide 1 mg^[10]. Both trials were open-label, SURMOUNT-5 was funded by tirzepatide’s maker and had no placebo group, and averages don’t predict how any one person will respond to or tolerate either drug^[10,11]. Which one fits a given person is for the prescriber to decide, based on the approved use, medical history and tolerance. The details are in the SURMOUNT-5 summary.

What happens if you miss a dose?

The US labels say a missed dose should be taken as soon as possible within 4 days (96 hours); if more than 4 days have passed, it’s skipped and the next dose is taken on the usual day^[1,2]. They also allow changing the day of the week as long as at least 3 days (72 hours) pass between two doses^[1,2]. What to do in your case is your prescriber’s call; if in doubt, ask your doctor or pharmacist.

Does tirzepatide cause thyroid cancer?

It caused thyroid C-cell tumors in rats; whether it does in humans is unknown. The US labels contraindicate it with a personal or family history of medullary thyroid carcinoma or MEN 2^[1,2]; the EU label doesn’t^[3]. If you have a history of thyroid disease, raise it with your prescriber.

Does tirzepatide affect birth-control pills?

The labels disagree. The US labels for Mounjaro and Zepbound advise switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase, because delayed stomach emptying may make the pill less effective^[1,2]. The EU label reports that after a single 5 mg dose, ethinyl estradiol peak levels fell 59% and total exposure 20%, but it doesn’t consider this clinically relevant and says no adjustment of oral contraceptives is needed^[3]. I go through both in period changes on Ozempic or Mounjaro. Ask your doctor or pharmacist what applies to you.

How long does tirzepatide stay in your body?

Its half-life is about 5 to 6 days, which is why one injection a week is enough, and steady blood levels are reached after 4 weeks of weekly injections^[1,2]. Because of that long half-life, the EU label says to stop it at least 1 month before a planned pregnancy^[3].

Can Zepbound treat sleep apnea?

In the US, yes: it’s approved for moderate to severe obstructive sleep apnea in adults with obesity, with maintenance doses of 10 or 15 mg^[1]. The FDA called it the first drug treatment option for certain patients with the condition^[7]. In the EU, the sleep apnea results are described in the label but aren’t a separate indication^[3].

Is it safe to buy tirzepatide online or through social media?

No. The FDA warns that compounded products aren’t reviewed for safety, effectiveness or quality^[17], and the EMA that illegal products sold as tirzepatide may not contain it at all^[18]. The EMA’s advice is to talk to a doctor and buy only with a prescription from legitimate retailers^[18].

Do I need to tell my doctor if I’m having surgery or an endoscopy with sedation?

Yes. The US and EU labels describe pulmonary aspiration during general anesthesia or deep sedation in people on GLP-1 receptor agonists, and the US labels ask patients to tell their healthcare providers about any planned procedure^[1,2,3]. What to do with the medicine beforehand is for the team treating you to decide.

Before you decide anything, talk to your prescriber

Tirzepatide has benefits measured in large trials, side effects well described in its labels, and open questions, such as what happens long term after stopping it. The dose, any changes and the decision to continue or stop are for your doctor, with you. Bring your symptoms, the other medicines you take and your questions about this guide to the visit; the doctor visit checklist can help. I’ll review this page every quarter, and sooner if a label changes or a regulator publishes something new.